A2 to O Lung Transplants

Condition(s) studied

Investigational drug(s) / intervention(s)

Blood group A2 donor to blood group O recipient lung transplant surgery: Suitable blood group A2 donor lung transplant to a consented blood group O recipient who has acceptably low levels of anti-A antibody titres and a negative virtual cross-match at time of transplant

Study summary

Blood group A2 to blood group O kidney and liver transplants have been shown to be safe and successful, especially in recipients with low pre-operative anti-A antibody titers and with the use of peri-operative antibody-depleting therapies. Since blood group O lung transplant candidates tend to have longer wait times and a higher waitlist mortality compared to other blood groups, we propose to conduct a prospective study of lung transplantation from blood group A2 donors to eligible blood group O recipients in an effort to increase the available donor pool. The aim of this study is to determine both the feasibility and safety of this specific type of ABO-incompatible lung transplant, and the impact of this practice on reducing transplant wait times among blood group O lung transplant candidates. This would represent the first prospective study of ABO-incompatible lung transplants worldwide.

Eligibility

Primary outcome measure(s)

• Post-transplant anti-A antibody titers — post-op day 5 or day 12
• Primary graft dysfunction grade — post-op day 0, 1, 2, 3
• Incidence of hyperacute antibody-mediated rejection — post-op day 1, 2
• C4d positivity on transbronchial biopsy samples — 1 year
• Incidence and severity of acute cellular rejection — 1 year
• Bleeding — post-op day 1-7
• Infection — 10 years
• Graft function — 10 years
• Incidence of malignancy — 10 years
• Chronic lung allograft dysfunction — 10 years
• Time to death or re-transplantation — 10 years

Trial sites (1)

More University Health Network, Toronto trials in Canada

Other trials for the same condition